

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

June 23, 2020

Saiid Zarrabian Chief Executive Officer DelMar Pharmaceuticals, Inc. 12707 High Bluff Drive, Suite 200 San Diego, CA 92130

Re: DelMar Pharmaceuticals, Inc.
Registration Statement on Form S-4
Filed June 16, 2020
File No. 333-239215

Dear Mr. Zarrabian:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Paul Fischer at 202-551-3415 with any questions.

Sincerely,

Division of Corporation Finance Office of Life Sciences

cc: Steve Skolnick, Esq.